Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Furosemide + spironolactone is a fixed-dose combination of two diuretics used primarily to treat edema (fluid overload) associated with heart failure, liver cirrhosis, kidney disease, or lung disease, as well as for the management of hypertension in certain cases. Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the thick ascending limb of the loop of Henle, leading to increased excretion of water and electrolytes. Spironolactone is a potassium-sparing diuretic and aldosterone antagonist that blocks mineralocorticoid receptors in the distal nephron, promoting sodium excretion while conserving potassium. The combination provides synergistic diuresis while minimizing potassium loss compared to furosemide alone[1][2][3][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on furosemide + spironolactone.